AMRN Stock Overview
A pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Amarin Corporation plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.46 |
| 52 Week High | US$1.37 |
| 52 Week Low | US$0.43 |
| Beta | 1.84 |
| 1 Month Change | -8.59% |
| 3 Month Change | -24.41% |
| 1 Year Change | -49.24% |
| 3 Year Change | -86.37% |
| 5 Year Change | -97.88% |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues
Oct 29
Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 29% Above Their Intrinsic Value Estimate
Aug 01Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues
Jun 06Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Apr 16Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding
Mar 12Amarin: Sarissa Is Giving Me Hope Again
Jan 15Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified
Jan 03Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)
Nov 19Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel
Sep 27We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth
Jul 18Is Amarin (NASDAQ:AMRN) In A Good Position To Deliver On Growth Plans?
Nov 11Amarin gains as activist Sarissa starts process for special meeting to replace some board members
Oct 11Amarin down 21% on higher than normal daily volume
Aug 22For Amarin, Something Wishful This Way Comes
Aug 14Shareholder Returns
| AMRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.9% | 2.1% | 2.8% |
| 1Y | -49.2% | -3.8% | 24.5% |
Return vs Industry: AMRN underperformed the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: AMRN underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| AMRN volatility | |
|---|---|
| AMRN Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AMRN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AMRN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 275 | Aaron Berg | www.amarincorp.com |
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers.
Amarin Corporation plc Fundamentals Summary
| AMRN fundamental statistics | |
|---|---|
| Market cap | US$187.86m |
| Earnings (TTM) | -US$39.35m |
| Revenue (TTM) | US$241.02m |
0.8x
P/S Ratio-4.8x
P/E RatioIs AMRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMRN income statement (TTM) | |
|---|---|
| Revenue | US$241.02m |
| Cost of Revenue | US$104.95m |
| Gross Profit | US$136.07m |
| Other Expenses | US$175.42m |
| Earnings | -US$39.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | 56.46% |
| Net Profit Margin | -16.32% |
| Debt/Equity Ratio | 0% |
How did AMRN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 00:43 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amarin Corporation plc is covered by 24 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Chiara Russo | Cantor Fitzgerald & Co. |
| Andrew Fein | Chardan Capital Markets, LLC |